Fluvoxamine for the treatment of COVID-19
| Errataetall: |
CommentOn: Lancet Glob Health. 2022 Jan;10(1):e42-e51. - PMID 34717820 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
The Lancet. Global health - 10(2022), 3 vom: 08. März, Seite e332 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dodds, Michael G [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 24.02.2022 Date Revised 07.12.2022 published: Print ClinicalTrials.gov: NCT04510194, NCT04885530 CommentOn: Lancet Glob Health. 2022 Jan;10(1):e42-e51. - PMID 34717820 Citation Status MEDLINE |
|---|
| doi: |
10.1016/S2214-109X(22)00006-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM33712275X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM33712275X | ||
| 003 | DE-627 | ||
| 005 | 20231225233707.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S2214-109X(22)00006-7 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1123.xml |
| 035 | |a (DE-627)NLM33712275X | ||
| 035 | |a (NLM)35180412 | ||
| 035 | |a (PII)S2214-109X(22)00006-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dodds, Michael G |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Fluvoxamine for the treatment of COVID-19 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.02.2022 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a ClinicalTrials.gov: NCT04510194, NCT04885530 | ||
| 500 | |a CommentOn: Lancet Glob Health. 2022 Jan;10(1):e42-e51. - PMID 34717820 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Comment | |
| 650 | 7 | |a Fluvoxamine |2 NLM | |
| 650 | 7 | |a O4L1XPO44W |2 NLM | |
| 700 | 1 | |a Doyle, Eileen B |e verfasserin |4 aut | |
| 700 | 1 | |a Reiersen, Angela M |e verfasserin |4 aut | |
| 700 | 1 | |a Brown, Fran |e verfasserin |4 aut | |
| 700 | 1 | |a Rayner, Craig R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Lancet. Global health |d 2013 |g 10(2022), 3 vom: 08. März, Seite e332 |w (DE-627)NLM237515954 |x 2214-109X |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2022 |g number:3 |g day:08 |g month:03 |g pages:e332 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/S2214-109X(22)00006-7 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2022 |e 3 |b 08 |c 03 |h e332 | ||